Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of “Buy” by Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned an average rating of “Buy” from the seventeen ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $155.60.

A number of research firms recently weighed in on PVLA. Truist Financial raised their target price on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 22nd. BTIG Research boosted their target price on shares of Palvella Therapeutics from $167.00 to $192.00 and gave the stock a “buy” rating in a report on Monday, December 15th. TD Cowen increased their price target on shares of Palvella Therapeutics from $97.00 to $133.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, December 16th.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics in the 3rd quarter worth about $28,000. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the 3rd quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Palvella Therapeutics in the second quarter worth about $37,000. JPMorgan Chase & Co. boosted its position in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics during the second quarter valued at approximately $85,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Down 2.2%

Shares of Palvella Therapeutics stock opened at $101.14 on Thursday. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $114.69. The business has a 50-day moving average price of $89.31 and a 200-day moving average price of $60.97. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -38.46 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, equities analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.